Prognostic value of microRNAs profiling in early stage squamous cell lung cancer Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009
The risk of distant metastases and prognosis prediction in early stage squamous cell lung cancer (SqCLC) by means of 3 microRNAs expression assessment Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010
FEV1 is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results Year: 2011
Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm Source: Eur Respir J 2010; 36: 1355-1361 Year: 2010
The value of AXL expression in squamous cell carcinoma of the lung: relationship with clinicopathological parameters. Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement Source: Eur Respir J 2007; 30: 21-26 Year: 2007
Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002
Prognostic value of apoptotic index (AI) considered jointly with cell cycle regulators in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
The expression of Ki-67, a marker of proliferative activity, in resected nonsmall cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
COX-2 expression during early lung squamous cell carcinomas oncogenesis Source: Eur Respir J 2005; 26: Suppl. 49, 456s Year: 2005
Analysis of surgical stage lung cancer and tumour markers prognostic value Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006
Prognostic value of Her2/neu in stage IIIA non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006
Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Prognostic significance of Nestin in resected non-small cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Assessment of DNA ploidy and proliferating activity changes in neoplasmatic cells according to TNM classification and clinical stages in non-small cell lung cancer (NSCLC) patients during chemotherapy Source: Eur Respir J 2003; 22: Suppl. 45, 225s Year: 2003
Differentiation between squamous cell carcinoma (SCC) and adenocarcinoma (AC): Expression of immunohistochemical (IHC) markers in a tissue microarray (TMA) of >1000 NSCLC Source: Annual Congress 2011 - Molecular pathology and functional genomics of lung disease Year: 2011